Spotlight on Orthopedics
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care
StartActivity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Activity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Orthopedics Presentations
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care
StartActivity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Activity Details
1.25 Contact Hour(s)
Expires: April 12, 2022
Accredited By
This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.
Target Audience
The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.
Learning Objectives
As a result of participation in this educational activity, participants should increase their ability to:
- Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
- Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
- Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.
Activity Description
The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.
To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.
Agenda
- Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
- Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
- Personalized Patient Cases
- Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time
Faculty
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin
Disclosure and Conflict of Interest Resolution
Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:
- Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
- Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
- Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
Faculty (Presenter): Phillip Mease, MD, MACR
- Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
- Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR
- Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi
Faculty (Planner): Richard Martin, MD, MA
- Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly
Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP
- Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
- Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
All of the relevant financial relationships listed for these individuals have been mitigated.
Accreditation Statement
Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Physicians
Forefront Collaborative designated this enduring activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Nurse Practitioners
This activity has been planned and
implemented in accordance with the Accreditation Standards of the American
Association of Nurse Practitioners (AANP) through the joint providership of
AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH
Inc., Advancing Knowledge in Healthcare is accredited by the American
Association of Nurse Practitioners as an approved provider of nurse
practitioner continuing education. Provider number: 030803.
This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer Statement/Disclosure of Unlabeled Use
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.
The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.
This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions About the Activity
Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.
Research Updates in Gout: Improving Response Rate to Therapy
StartActivity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
Activity Details
Expires: February 11, 2022
Accredited By
Target Audience
Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.
Learning Objectives
- Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
- Summarize the latest evidence related to complications associated with gout
- Incorporate evidence-based research into clinical practice
Activity Description
OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence
related to gout, as well as study results presented at the American College
of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger
begins with an introduction to this CME activity by touching on a recent
published systematic review indicating that the manifestations of gout extend
beyond the joints, affecting other organs and tissues. Dr. Schlesinger also
provides an overview of some of the challenges encountered in clinical
practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger
focuses on 2 abstracts presented at ACR Convergence 2020 concerning
gout-related comorbidities, particularly cardiovascular disease. In module 2,
Dr. Mandell focuses on 2 abstracts related to the safety and use of
urate-lowering therapy, specifically allopurinol, febuxostat, and
pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the
systemic nature of gout; 1 abstract focuses on heart failure, while the other
focuses on the lumbar spine.
CONTENT AREAS
- Systemic burden of gout
- Gout comorbidities
- Allopurinol
- Febuxostat
- Pegloticase
Statement of Educational Need
- Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
- Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
- Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs
Agenda
Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:
- Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
- Faculty reviews study methodology [1 min]
- For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
- Faculty summarizes key findings [3-4 min]
- How the data advances the current treatment landscape/paradigms
- How the data should be positioned among ongoing research
- How the data connects with current research imperatives
- Clinical significance/implications for current knowledge or practice
- Data one might be expected from the trial in the future
- Faculty provides commentary [5-8 min]
Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.
Faculty
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Conflict of Interest Policy/Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech
Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
The estimated time to complete the activity is 1.0 hour.
Statement of Commercial Support
This activity is supported by an educational grant from Horizon Therapeutics.
Disclaimer Statement/Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.
Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no
relevant commercial relationships to disclose.
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information for Questions About the Activity
For help or questions about this activity please contact Continuing
Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday
Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?
StartActivity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX
Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX
Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors
StartActivity Details
Expires: July 24, 2021
Accredited By
Target Audience
This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
- Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
- Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
Activity Description
How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.
Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.
Bonus supplemental material includes:
- Understanding Discordance in RA Care
- Patient Perspectives on Shared Decision-Making
- What Patients with RA Want Their Rheumatologists to Know
- EULAR 2020 RA Updates
Statement of Educational Need
Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.
As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.
Agenda
Clinical commentary highlights includes:
- Available and emerging JAK inhibitors
- Tactics for patients who may have a poor response to biologic treatment
- Role and adverse event management of small molecule drugs
- The latest treat-to-target paradigms
Chair
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR
Faculty
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH
Patient Ambassadors
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc.,
GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB
Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb,
Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun
Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer
Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly,
Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen,
Lilly, Novartis, Pfizer Inc., UCB
William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer
Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead
Sciences, Inc., Pfizer Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device
Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under
investigation for RA
Patient Ambassador Disclosures
Kelly O'Neill and Shannon Young, EdD, have no financial relationships.
Accreditation Statement
The
Academy for Continued Healthcare Learning is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Activity Details
Expires: July 24, 2021
Accredited By
Target Audience
This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
- Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
- Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
Activity Description
How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.
Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.
Bonus supplemental material includes:
- Understanding Discordance in RA Care
- Patient Perspectives on Shared Decision-Making
- What Patients with RA Want Their Rheumatologists to Know
- EULAR 2020 RA Updates
Statement of Educational Need
Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.
As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.
Agenda
Clinical commentary highlights includes:
- Available and emerging JAK inhibitors
- Tactics for patients who may have a poor response to biologic treatment
- Role and adverse event management of small molecule drugs
- The latest treat-to-target paradigms
Chair
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR
Faculty
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH
Patient Ambassadors
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc.,
GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB
Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb,
Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun
Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer
Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly,
Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen,
Lilly, Novartis, Pfizer Inc., UCB
William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer
Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead
Sciences, Inc., Pfizer Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device
Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under
investigation for RA
Patient Ambassador Disclosures
Kelly O'Neill and Shannon Young, EdD, have no financial relationships.
Accreditation Statement
The
Academy for Continued Healthcare Learning is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee
StartActivity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management
StartActivity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.